ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)

A dynamic tool to assess the magnitude of clinical benefit of cancer medicines.

The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost effective and affordable cancer care.

For more information on the scale check our factsheet and booklet!

Scorecards

Access the ESMO Scorecards by using the online filter, which allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting.

Articles

Check-out the articles on ESMO-MCBS published in the ESMO journals.

ESMO-MCBS and the WHO

The role of the ESMO-MCBS in the WHO Model List of Essential Medicines.

Presentations

Over the years, the scale has been presented on several occasions at the ESMO Congresses.

Check out the session webcasts!

ESMO-MCBS Working Group

The ESMO-MCBS Working Group is committed in maintaining and updating the scale

Introducing the ESMO-MCBS

In 2015 ESMO published the ESMO-MCBS. On its launch, Fortunato Ciardiello, Elisabeth de Vries, Josep Tabernero and Alexandru Eniu introduced the ESMO-MCBS and its importance in facilitating improved decision-making regarding the value of anti-cancer therapies, promoting the accessibility and reducing iniquity of access to high value cancer treatments.

For further information about the ESMO-MCBS, please send an email to mcbs@esmo.org